Indeed, blocking this signalling pathway through use of anti-TNF-α (infliximab) (94, 95) or anti-TNFR1 (96) antibodies in rodent models of NAFLD, led to significant improvement of liver steatosis, inflammation, insulin resistance and extent of liver fibrosis. The gene discussed is TNFRSF1A; the disease is metabolic dysfunction-associated steatotic liver disease.